Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Inventory (2018 - 2025)

BioNexus Gene Lab's Inventory history spans 8 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Inventory fell 27.47% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.0 million, down 27.47%, while the annual FY2024 figure was $1.4 million, 22.05% up from the prior year.
  • Inventory for Q3 2025 was $1.0 million at BioNexus Gene Lab, down from $1.2 million in the prior quarter.
  • Across five years, Inventory topped out at $1.7 million in Q2 2021 and bottomed at $899636.0 in Q1 2023.
  • The 5-year median for Inventory is $1.2 million (2025), against an average of $1.3 million.
  • The largest annual shift saw Inventory surged 20274.32% in 2021 before it crashed 45.44% in 2023.
  • A 5-year view of Inventory shows it stood at $1.5 million in 2021, then crashed by 35.75% to $977807.0 in 2022, then increased by 16.36% to $1.1 million in 2023, then increased by 22.05% to $1.4 million in 2024, then fell by 27.45% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Inventory are $1.0 million (Q3 2025), $1.2 million (Q2 2025), and $1.2 million (Q1 2025).